Skip to main content

Table 1 Baseline characteristics stratified by vital status at the end of follow-up

From: Association of prognostic nutritional index level and diabetes status with the prognosis of coronary artery disease: a cohort study

Variable

All participants (n = 9429)

Deceased (n = 366)

Survival (n = 9063)

p

Demographic characteristics

 Sex (Women)

2162 (22.93)

95 (25.96)

1067 (22.81)

0.160

 Age, years

59 [51, 66]

66 [58, 73]

58 [51, 65]

 < 0.001

  ≥ 65

2623 (27.82)

203 (55.46)

2420 (26.70)

 < 0.001

 BMI, kg/m2

25.91 [23.88, 27.76]

25.71 [23.40, 27.73]

25.91 [23.94, 27.76]

0.052

  ≥ 25

5742 (60.90)

213 [58.20]

5529 (61.01)

0.280

 Current smoking

5363 (56.88)

210 (57.38)

5153 (56.86)

0.844

Clinical characteristics

 Clinical presentation

0.642

 ACS

5583 (59.21)

221 (60.38)

5362 (59.16)

 

 CCS

3846 (40.79)

145 (39.62)

3701 (40.84)

 

 Hypertension

6576 (69.74)

291 (79.51)

6285 (69.35)

 < 0.001

 Dyslipidemia

7121 (75.52)

269 (73.50)

6852 (75.60)

0.358

 Diabetes

3956 (41.96)

189 (51.64)

3767 (41.56)

 < 0.001

 Peripheral artery disease

252 (2.67)

16 (4.37)

236 (2.60)

0.040

COPD

220 (2.33)

24 (6.56)

196 (2.16)

 < 0.001

 Previous revascularization

2468 (26.17)

134 (36.61)

2334 (25.75)

 < 0.001

 Previous MI

1826 (19.37)

92 (25.14)

1734 (19.13)

0.004

 Previous stroke

990 (10.50)

51 (13.93)

939 (10.36)

0.029

Medication at admission

 Aspirin

9315 (98.79)

359 (90.09)

8956 (98.82)

0.209

 Clopidogrel

9412 (99.82)

365 (99.73)

9047 (99.82)

0.576

 Statins

9051 (95.99)

351 (95.90)

8700 (95.99)

0.929

 β-blockers

8493 (90.07)

323 (88.25)

8170 (90.15)

0.234

 ACEIs/ARBs

4929 (52.27)

204 (55.74)

4725 (52.14)

0.176

Preprocedural laboratory tests

 ALC, 109/L

1.87 [1.51, 2.30]

1.76 [1.45, 2.20]

1.87 [1.51, 2.31]

 < 0.001

 Serum albumin, g/L

42.70 [39.90, 45.90]

41.30 [38.70, 44.60]

42.80 [40.00, 45.90]

 < 0.001

 PNI

52.60 [49.00, 56.15]

50.98 [46.70, 54.65]

52.65 [49.05, 56.25]

 < 0.001

 hs-CRP, mg/L

1.60 [0.80, 3.59]

2.08 [1.05, 5.25]

1.58 [0.79, 3.54]

 < 0.001

 Fasting blood glucose, mmol/L

5.48 [4.93, 6.63]

5.70 [5.04, 7.08]

5.47 [4.93, 6.62]

 < 0.001

 Glycated hemoglobin, %

6.2 [5.8, 6.9]

6.4 [6.0, 7.3]

6.2 [5.8, 6.9]

0.002

 eGFR, ml/min/1.73m2

118.11 [102.63, 133.24]

111.64 [89.10, 127.53]

118.27 [10.300, 133.50]

 < 0.001

  ≤ 60

92 (0.98)

16 (4.37)

76 (0.84)

 < 0.001

 LVEF, %

64 [60, 67]

62 [58, 66]

64 [60, 67]

 < 0.001

  < 40

102 (1.08)

14 (3.83)

88 (0.97)

 < 0.001

Angiographic characteristics

 LM/TVD

412 (4.37)

18 (4.92)

394 (4.35)

0.601

 SYNTAX score

10 [6, 17]

10 [5, 17]

10 [6, 17]

0.911

 SYNTAX category

0.110

  ≤ 22

8367 (88.74)

313 (85.52)

8054 (88.87)

 

 22–32

893 (9.47)

43 (11.75)

850 (9.38)

 

  ≥ 33

169 (1.79)

10 (2.73)

159 (1.75)

 

 DES implantation

8950 (94.92)

340 (92.90)

8610 (95.00)

0.072

  1. Values are presented as number (%) or median [interquartile range]
  2. ACEI angiotensin-converting enzyme inhibitor, ACS acute coronary syndrome, ALC absolute lymphocyte counts, ARB angiotensin-receptor blocker, BMI body mass index, CCS chronic coronary syndrome, COPD chronic obstructive pulmonary disease, DES drug-eluting stent, eGFR estimated glomerular filtration rate, hs-CRP high-sensitivity C-reactive protein, LM/TVD left main or three-vessel disease, LVEF left ventricular ejection fraction, MI myocardial infarction, PNI prognostic nutritional index, SYNTAX synergy between percutaneous coronary intervention with Taxus and cardiac surgery
Back to article page

Diabetology & Metabolic Syndrome

ISSN: 1758-5996

Contact us